Bracco and Zereau Join Forces for Innovative Research Program Aimed at Improving Sustainability in Medical Imaging
Bracco Imaging SpA, a world leader in diagnostic imaging and Zereau BV, a provider of unique water technology for the ...
Hosted on MSN21d
FDA fast tracks Bracco’s BR55 for Crohn’s disease bowel inflammation detection
The US Food and Drug Administration (FDA) has granted fast track designation for the development of Bracco Imaging's molecular imaging ultrasound contrast agent, BR55, to identify active bowel ...
Monthly Prescribing Reference23d
VEGFR2-Binding Contrast Agent Fast Tracked for Crohn Disease Assessment
BR55 injection, an investigational contrast agent for ultrasounds ... Chief Medical and Regulatory Officer, Bracco Imaging Group. “This Fast Track designation supports our goal to get BR55 ...
Morningstar2d
Bracco and Zereau Join Forces for Innovative Research Program Aimed at Improving Sustainability in Medical Imaging
is a significant step toward minimizing the environmental footprint of contrast media use in medical imaging. "As a leader in medical imaging, Bracco recognizes that sustainability and innovation ...
Yahoo Finance21d
FDA fast tracks Bracco’s BR55 for Crohn’s disease bowel inflammation detection
The company is currently preparing for Phase III trials to further assess the efficacy and safety of the agent in identifying active inflammation in individuals with Crohn's disease. Credit ...
Bracco Group: Bracco and Zereau Join Forces for Innovative Research Program Aimed at Improving Sustainability in Medical Imaging
The two companies announced the launch of a study to reduce contrast media in wastewater through sustainable urine filtration systems for hospitals and diagnostic facilities MILAN, Feb.